Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Top 200 Medicines Annual Report 2018: Blockbusters thriving despite tumultuous climate

There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.

Read More »

Trump says will make announcement on reducing drug prices

U.S. President Donald Trump said his administration would make an announcement on reducing drug prices, but he did not offer specifics.

Read More »

Bayer wins EU watchdog’s endorsement for wider Xarelto use

Bayer received the European Medicines Agency’s recommendation for widening the use of its blockbuster clot prevention drug Xarelto to include atherosclerosis patients, opening a potentially lucrative new market.

Read More »

Amgen’s new migraine drug hits insurance hurdles

Amgen Inc.’s push to get patients on its new $575 a month migraine drug before competition emerges in September 2018 is facing barriers from insurers.

Read More »

Bayer to phase out Essure birth control device in U.S.

Bayer will discontinue the sale of the healthcare company’s birth control product Essure in the United States.

Read More »

Swiss, German drugmakers join U.S. price freeze

European drugmakers Roche, Bayer and Merck KGaA became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine.

Read More »

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc. signed a U.S. licensing deal for Mylan NV’s proposed biosimilar to the mega-blockbuster drug Humira.

Read More »

U.S. court blocks sale of Indivior rival generic

Indivior Plc’s shares jumped more than 33 percent after a U.S. court blocked a rival from selling a cheaper copycat of the British drugmaker’s bestselling opioid addiction treatment.

Read More »

Trump told Pfizer CEO price hikes hurt his drug plan: source

U.S. President Donald Trump called Pfizer Chief Executive Ian Read to say the company’s July 1 price hikes had complicated the administration’s drug pricing plans, prompting the company to defer its planned increases, according to a source familiar with the matter.

Read More »

Pfizer Raises Prices Of Forty-Plus Drugs Per Report

The Wall Street Journal reported that Pfizer increased the list prices for more than 40 of the pharma giant’s prescribed medications.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom